Canalicular Membrane MRP2/ABCC2 Internalization is Determined by Ezrin Thr567 Phosphorylation in Human Obstructive Cholestasis
Overview
Authors
Affiliations
Background & Aims: Multidrug resistance-associated protein 2 (MRP2) excretes conjugated organic anions including bilirubin and bile acids. Malfunction of MRP2 leads to jaundice in patients. Studies in rodents indicate that Radixin plays a critical role in determining Mrp2 canalicular membrane expression. However, it is not known how human hepatic MRP2 expression is regulated in cholestasis.
Methods: We assessed liver MRP2 expression in patients with obstructive cholestasis caused by gallstone blockage of bile ducts, and investigated the regulatory mechanism in HepG2 cells.
Results: Western blot detected that liver MRP2 protein expression in obstructive cholestatic patients (n=30) was significantly reduced to 25% of the non-cholestatic controls (n=23). Immunoprecipitation identified Ezrin but not Radixin associating with MRP2 in human livers, and the increased amount of phospho-Ezrin Thr567 was positively correlated with the amount of co-precipitated MRP2 in cholestatic livers, whereas Ezrin and Radixin total protein levels were unchanged in cholestasis. Further detailed studies indicate that Ezrin Thr567 phosphorylation plays an important role in MRP2 internalization in HepG2 cells. Since increased expression of PKCα, δ and ε were detected in these cholestatic livers, we further confirmed that these PKCs stimulated Ezrin phosphorylation and reduced MRP2 membrane expression in HepG2 cells. Finally, we identified GP78 as the key ubiquitin ligase E3 involved in MRP2 proteasome degradation.
Conclusions: Activation of liver PKCs during cholestasis leads to Ezrin Thr567 phosphorylation resulting in MRP2 internalization and degradation where ubiquitin ligase E3 GP78 is involved. This process provides a mechanistic explanation for jaundice seen in patients with obstructive cholestasis.
Drug-Induced Liver Injury Associated With Emerging Cancer Therapies.
Chodup P, Samodelov S, Visentin M, Kullak-Ublick G Liver Int. 2025; 45(2):e70002.
PMID: 39853863 PMC: 11760653. DOI: 10.1111/liv.70002.
Li M, He Y, Zhang M, Tang W, Tan Y, Cheng Y Cell Death Dis. 2024; 15(10):725.
PMID: 39358349 PMC: 11447222. DOI: 10.1038/s41419-024-07102-w.
Liao M, Yu W, Xie Q, Zhang L, Pan Q, Zhao N Gastro Hep Adv. 2024; 2(3):412-423.
PMID: 39132646 PMC: 11307722. DOI: 10.1016/j.gastha.2022.11.002.
Oligomerization of drug transporters: Forms, functions, and mechanisms.
Ni C, Hong M Acta Pharm Sin B. 2024; 14(5):1924-1938.
PMID: 38799641 PMC: 11119549. DOI: 10.1016/j.apsb.2024.01.007.
Genetics of Gallstone Disease and Their Clinical Significance: A Narrative Review.
Costa C, Nguyen M, Vaziri H, Wu G J Clin Transl Hepatol. 2024; 12(3):316-326.
PMID: 38426197 PMC: 10899874. DOI: 10.14218/JCTH.2023.00563.